Tempus AI (TEM, Financials) announced preliminary, unaudited financial results for 2024, reporting annual revenue of $693 million, a 30% year-over-year increase, and fourth-quarter revenue of $200 million, up 35%. Shares of Tempus fell 14.1% to $32.24 by 3:36 p.m. EST Monday, a $5.28 drop from the previous close.
While fourth-quarter income hit $200 million, showing 35% growth, the business said that yearly sales reached around $693 million, a 30% year-over-year rise.
Strong success in its core businessesincluding genomics revenue, which rose over 30% in the fourth quarteras well as data and services revenue, which climbed by almost 45%, helped the firm explain its revenue surge.
Despite softness in the contract research organization revenues, core businesses gained momentum throughout the year, Tempus founder and CEO Eric Lefkofsky said in the statement.
Tempus underlined that although the firm finishes its year-end financial assessment, the numbers are just preliminary and unaudited; they will inevitably alter. During its first earnings call of 2025, the business intends to finish and present these findings.
The company's announcement also contained information on its planned Ambry Genetics purchase. According to the announcement, Tempus is slated to offer further specifics during the 43rd Annual J.P. Morgan Healthcare Conference.
Tempus bills itself as promoting artificial intelligence-based precision medicine.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。